ceftriaxone pharmsol 1000 mg pulveris injekciju/infūziju šķīduma pagatavošanai
pharmsol europe limited, malta - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg
skysona
bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - other nervous system drugs - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.
salapime 1 g pulveris injekciju/infūziju šķīduma pagatavošanai
unifarma, sia, latvia - cefepīms - pulveris injekciju/infūziju šķīduma pagatavošanai - 1 g
xonvea 10 mg/10 mg zarnās šķīstošās tabletes
exeltis baltics uab, lithuania - doxylamini hydrogenosuccinas, pyridoxini hydrochloridum - zarnās šķīstošā tablete - 10 mg/10 mg
ceftriaxone kalceks 1 g pulveris injekciju/infūziju šķīduma pagatavošanai
kalceks, a/s, latvia - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 1 g
ceftriaxone kalceks 2 g pulveris injekciju/infūziju šķīduma pagatavošanai
kalceks, a/s, latvia - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 2 g
ceftriaxone venus pharma 1 g pulveris injekciju/infūziju šķīduma pagatavošanai
venus pharma gmbh, germany - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 1 g
ceftriaxone venus pharma 2 g pulveris injekciju/infūziju šķīduma pagatavošanai
venus pharma gmbh, germany - ceftriaksons - pulveris injekciju/infūziju šķīduma pagatavošanai - 2 g
xonvea 20 mg/20 mg modificētās darbības tabletes
exeltis baltics uab, lithuania - doxylamini hydrogenosuccinas, pyridoxini hydrochloridum - modificētās darbības tablete - 20 mg/20 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.